A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia.
Journal
Heliyon
Journal Volume
10
Journal Issue
21
Pages
e39698
ISSN
2405-8440
Date Issued
2024-11-15
Author(s)
Chng, Wee-Joo
Nagarajan, Chandramouli
Malhotra, Pankaj
Hwang, Yu-Yan
Blunk, Vivian
Singh, Manmohan
Wang, Lin
Abstract
Multiple myeloma (MM) accounts for almost 15 % of all neoplastic malignancies around the globe. This systematic review intends to analyse data on the treatment and management of MM in selected regions in Asia to identify and prioritize areas that need attention. A comprehensive review of original articles, published in English from 2005 to 2022, derived from the PubMed/MEDLINE database was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. There were 98 studies from select regions of Asia (China, India, Taiwan, Hong Kong, and Singapore) on newly diagnosed MM and relapsed/refractory MM. This review evaluated the trends in disease outcomes with the gradual shift in treatment regimens from doublet to triplet. Additionally, this review also explored autologous stem cell transplant outcome and anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy in MM patients. This is the first systematic review attempting to collect data on the utility and comparison of innovative agents and modifications in treatment regimens in the context of the Asian population. This review established that the body of evidence for the management of MM was generally of poor quality and there is a need for more versatile studies in the region. Novel and innovative drug regimens may help in combating the illness but consorted efforts by researchers, industry partners, policymakers, and the government are key factors in the long-term survival of MM patients. In the current systematic review, the authors have tried to give a comprehensive account of the available treatments, trends in MM management and prognosis for MM in Asia.
Subjects
Autologous stem cell transplant
B-cell maturation antigen targeted chimeric antigen receptor T-cell therapy
Newly diagnosed multiple myeloma
Proteasome inhibitors
Relapsed/refractory multiple myeloma
Type
journal article